Photobiomodulation: A Modern Approach for Precision PRP Therapy

Gain insights into precision PEP therapy with photobiomodulation and its role in modern therapeutic practices. Enhance your knowledge today.

Abstract

In this educational post, I walk you through how I design and deliver precision platelet-rich plasma (PRP) and protein concentrate therapies for musculoskeletal care, including osteoarthritis and shoulder pathology. I cover platelet dose recovery, hematologic quality metrics, leukoreduction, and a 10-minute single-spin method that yields high, reproducible platelet doses. I explain why platelet-poor plasma (PPP) is not “waste” but rather the backbone of a potent protein concentrate rich in anti-catabolic and anti-inflammatory mediators such as alpha-2-macroglobulin (A2M) and interleukin-1 receptor antagonist (IL-1ra), and how fluid reduction with a 15-kDa filter concentrates proteins and “rescues” additional platelets. I detail a step-by-step technique for creating this protein concentrate from PPP and discuss its clinical integration with ultrasound-guided acromioclavicular (AC) joint PRP injections, rehabilitation, photobiomodulation, and thermal therapies. I also address pre-procedure consult essentials, medication and supplement considerations, hydration, fasting debates, and cost transparency. Along the way, I discuss key clinical scenarios such as meniscectomy-associated OA progression and how integrative chiropractic care complements orthobiologic interventions through kinetic-chain assessment, graded loading, neuromuscular control, and lifestyle modulation. Throughout, I synthesize current research and provide a physiological rationale for each technique, anchoring every choice to mechanism, outcome, and patient-centered precision.

By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Visit: healthcoach.clinic/ and www.linkedin.com/in/dralexjimenez/

High-Performance PRP: Why Platelet Dose, Purity, and Versatility Matter

When I discuss “quality” in PRP, I start with three pillars: platelet dose recovery, purity of the injectate, and the system’s versatility.

• Platelet dose recovery: In my clinic, our average platelet recovery is approximately 83%, with frequent recoveries exceeding that when the sample metrics are ideal. Platelets distribute between plasma/serum and the red blood cell (RBC) stack; extracting the buffy coat effectively while minimizing RBC carryover is the art and science of reproducible PRP.
• Versatility and control: I prioritize systems that let me precisely harvest from the buffy coat and the platelet-rich layer at the top of the RBC stack. This flexibility allows me to dial in:

• • Volume (ccs) to match joint capacity or multi-site needs
  • Leukocyte profile (leukocyte-poor vs leukocyte-reduced options)
  • Red cell minimization

• Output: From a single 60-cc draw, I target an average of about 10.8 billion platelets in the final dose, often representing roughly a 10x concentration from whole-blood baseline.

Why is this important? In the literature, absolute platelet dose correlates better with clinical effect than concentration alone. The absolute dose relates to the number of growth factor packets delivered into the tissue. Higher doses within the therapeutic window support increased cellular signaling for repair, modulation of angiogenesis, and resolution of inflammation (Chahla et al., 2017; Mautner et al., 2015).

Key concept: Absolute platelet dose, purity (fewer RBCs and undesirable granulocytes), and consistent processing drive outcomes. My protocols anchor on these metrics—not just the “x-fold” label.

Inside the Numbers: Hematologic Metrics and a 94% Recovery Example

I continuously validate performance with hematology data. In a representative case:

• Whole blood platelet count: 265 x 10^3/µL
• Total platelets in 60 cc: approximately 15.9 billion
• Final injectate: 7 cc PRP at 2,128 x 10^3/µL
• Final dose delivered: approximately 14.89 billion platelets

That’s a 94% recovery in this specific sample. Additionally, granulocytes were reduced from whole blood, and RBC contamination in the platelet-rich fraction (PRP/PMP) was <0.1%. These purity metrics matter. Excess granulocytes can amplify catabolic cytokines and proteases in sensitive tissues; RBCs and hemolysis can drive oxidative stress and pain sensitization (Fitzpatrick et al., 2017).

Mechanistic rationale:

• Reducing RBCs and granulocytes decreases catabolic noise and oxidative burden.
• Maximizing platelet dose enhances delivery of stored factors such as PDGF, TGF-?, VEGF, IGF-1, and EGF, which orchestrate chemotaxis, angiogenic normalization, cellular proliferation, and matrix synthesis in the microenvironments of tendons, ligaments, and cartilage (Andia & Maffulli, 2013; Chahla et al., 2017).

Why Platelet-Poor Plasma Is “Liquid Gold”: Protein Concentrate and Anti-Catabolic Strategy

Historically, many clinicians discarded platelet-poor plasma (PPP). Today, we know PPP contains:

• Residual platelets
• Alpha-2-macroglobulin (A2M)
• Hepatocyte growth factor (HGF)
• Soluble TNF receptors (sTNF-R)
• PDGF-BB
• IL-1 receptor antagonist (IL-1ra)
• EGF
• And a large water fraction

By passing the PPP through a pre-wetted ~15-kDa fluid-reduction filter, I reliably dehydrate the sample by about 75%. This concentrates key proteins, improving therapeutic ratios:

• A2M: A broad-spectrum protease inhibitor that binds and sequesters catabolic enzymes such as ADAMTS and MMPs, curbing cartilage matrix degradation. Because A2M (~720 kDa) is large, direct synovial migration is limited; when we inject a concentrated product intra-articularly, A2M can “lure” and irreversibly bind degradative enzymes right where they’re active (Wang et al., 2014).
• IL-1ra: The natural antagonist of IL-1?/?, competitively blocks the IL-1 receptor, blunting NF-?B-mediated synovitis and cartilage catabolism. A protein concentrate can deliver an IL-1ra: IL-1? ratio that is clinically meaningful—approaching or exceeding 100:1 in my experience with optimized concentrates (Filardo et al., 2019).
• sTNF-R: Binds TNF-?, reducing its downstream inflammatory signaling.
• HGF: Exerts anti-fibrotic and immunomodulatory effects, beneficial for joint and tendon environments.
• Additional “rescued” platelets: With leukoreduction and fluid reduction, we often scavenge approximately 1.6 billion additional platelets from PPP—boosting the final total dose.

Clinical takeaway: PPP is not waste. It is a reservoir of anti-catabolic and pro-resolution molecules. Concentrating PPP into a protein-rich injectate can complement PRP to address both catabolic enzyme activity (A2M) and cytokine-driven inflammation (IL-1ra, sTNF-R), thereby shifting the joint milieu toward homeostasis.

Step-by-Step: Converting PPP to a Concentrated Protein Product

Below is my streamlined method with sterile technique maintained throughout:

1. Prepare the system:

• • Remove red caps from the 90-degree connector and the filter port.
  • Confirm stopcock orientation and secure all connections.

• Attach filters and syringes:

• • Remove the cap from the small green air filter; attach PPP on the opposite side.
  • Remove the blue cap from the stopcock and connect it to the port.
  • Confirm stopcock position.

• Prime and air management:

• • Gently push PPP to prime the fluid-reduction filter and expel air.
  • Replace the cap on the small green air filter once primed.

• Volume reduction setup:

• • Remove the second blue cap on the stopcock and attach an empty 60-mL syringe.
  • Attach the Vac-Lok syringe to the distal end of the filter, then retract the plunger to create a vacuum for water capture.

• Reciprocal “tabletop push”:

• • Use the tabletop method to shuttle fluid between syringes through the filter. Water accumulates in the Vac-Lok syringe; the product becomes progressively concentrated.
  • Aim for approximately 75% volume reduction.

• Final capture:

• • Once no residual plasma remains in either syringe and the target reduction is achieved, orient the stopcock to isolate the product.
  • Remove the Vac-Lok, recap the filter, open the small air filter briefly to allow minimal air entry for displacement, and withdraw the concentrated protein product—the “liquid gold.”

This approach enhances the concentration of high-value proteins without denaturing them, while maintaining low leukocyte and RBC content. The physiological rationale is straightforward: increased concentration means a higher local bioactive dose at the site of pathology, which can neutralize catabolic cascades and reduce synovitis more effectively than PRP alone in certain osteoarthritic contexts (Xie et al., 2021).

Osteoarthritis Strategy: Marrying PRP with Protein Concentrate

Osteoarthritis (OA) is a whole-joint disease with:

• Synovial inflammation driven by IL-1, TNF-?
• Cartilage matrix degradation via MMPs and ADAMTS
• Subchondral bone remodeling and bone marrow lesions
• Sensitization and neurogenic inflammation

How I combine therapies:

• PRP delivers growth factors and chemotactic signals to support chondrocyte anabolism, synovial membrane modulation, and normalization of subchondral crosstalk.
• Protein concentrate delivers high A2M to “mop up” proteases and high IL-1ra with sTNF-R to blunt inflammatory cytokine signaling.

Why this dual approach:

• PRP alone is anabolic/pro-resolving, but in moderately inflamed joints, protease and cytokine loads can outpace anabolism. Adding a concentrated anti-catabolic/anti-inflammatory fraction rebalances the equation, protecting the matrix while PRP signals repair (Saltzman et al., 2016; Filardo et al., 2019).
• Clinically, I observe improved pain and function at 6–12 weeks when pairing PRP with a protein concentrate in symptomatic OA, particularly in patients with effusions or ultrasound signs of synovitis.

Integrative Chiropractic Care: The Kinetic Chain That Protects Your Biology Investment

Orthobiologics change the chemistry; integrative chiropractic changes the mechanics. At Health Coach Clinic, my model integrates:

• Detailed biomechanical assessment:

• • Gait, single-leg stance, valgus/varus control
  • Hip strategy vs knee strategy during squats and step-downs
  • Scapulothoracic rhythm and cervical-thoracic posture in shoulder patients

• Targeted manual therapy:

• • Joint mobilization to restore accessory motion
  • Soft-tissue techniques to normalize tone and improve glide

• Neuromuscular retraining:

• • Eccentric-biased loading for tendons
  • Proximal hip strengthening to reduce knee joint loads
  • Serratus anterior and lower trapezius activation for shoulder centration

• Lifestyle modulation:

• • Anti-inflammatory nutrition, sleep optimization, weight management, and stress physiology regulation to reduce systemic inflammatory tone

Why it matters: If you inject a biologic into a joint still exposed to aberrant loads and motor control errors, you are asking biology to fight physics. Integrative chiropractic closes that loop, reinforcing the new biochemical environment with better force distribution and movement quality (Bittencourt et al., 2016). Over time, this synergy improves the durability of outcomes and reduces the risk of reinjury.

Clinical observation: In my practice, coupling PRP/protein concentrate with graded loading, manual care, and sensorimotor work has meaningfully reduced flare rates, particularly in patellofemoral OA and rotator cuff tendinopathy, and has accelerated return-to-activity timelines.

Learn more: healthcoach.clinic/ and www.linkedin.com/in/dralexjimenez/.

Ultrasound-Guided AC Joint PRP Injection: Practical Technique and Rationale

For AC joint pathology, I typically position the patient seated and use an out-of-plane approach, entering posterior-to-anterior while keeping the transducer anterior.

• Preparation:

• • Mark the site; prep with betadine and alcohol.
  • Local anesthesia is placed strategically to minimize injectate dilution.

• Needle targeting:

• • Center the AC joint on ultrasound; the target is typically 1.5 cm deep, in the “V” of the joint line.
  • Visualize the hyperechoic needle tip (“bright white dot”) adjacent to bone; then advance into the joint space.

• Injection:

• • The AC joint typically accepts ~0.6–1.1 cc of PRP; the injectate should flow freely without significant resistance.

Why out-of-plane? For this small joint, the out-of-plane trajectory with constant-tip visualization improves speed and ergonomics during multi-structure sessions (e.g., glenohumeral joint, supraspinatus, subscapularis, biceps tendon) while maintaining safety.

Physiological targets:

• PRP modulates synovitis, supports capsuloligamentous tissue health, and may normalize nociceptive signaling at the acromioclavicular articulation.
• A leukocyte-reduced profile minimizes post-injection irritation in small, sensitive synovial spaces.

Comprehensive Shoulder Sessions: Efficient Sequencing and Safety

In multi-site shoulder work, efficient sequencing matters:

• Typical order (if multiple targets are planned):

1. 1. Posterior glenohumeral joint
   2. AC joint intra-articular
   3. Infraspinatus insertion
   4. Supraspinatus intratendinous
   5. Subscapularis intratendinous
   6. Long and short-axis biceps groove

• Gauge selection:
  • I often use a 25G needle for the AC joint and many tendon targets to balance control and patient comfort.

• Safety and positioning:

• • Seated position is efficient, but anticipate vasovagal risk; be ready to convert to lateral decubitus swiftly.

Clinical rationale: Consolidating targets into a single session, when appropriate, reduces the overall procedural burden and improves coordination with rehabilitation, provided we respect tissue-specific load progression and healing timelines.

Post-Procedure Care: Sling, Laser, Thermal Strategies, and Rehab Timing

My standard shoulder post-protocol:

• Sling: 1–2 days for comfort and to “signal” activity modification.
• Photobiomodulation: Begin the day after procedure (often same-day in select cases).

• • Mechanism: Low-level light enhances mitochondrial cytochrome c oxidase activity, increasing ATP availability and nitric oxide signaling, thereby supporting cellular metabolism and analgesia without the risk of proliferative dysplasia at therapeutic doses (Hamblin, 2017).

• Thermal modalities:

• • Prefer near-infrared or moist heat for comfort and microcirculatory support.
  • Ice can blunt cellular metabolism and may slow the inflammatory-to-proliferative transition; I reserve it only for intractable post-injection discomfort.

• Anti-inflammatories:

• • Avoid NSAIDs for approximately two weeks post-procedure to preserve platelet function and early inflammation-to-repair signaling.
  • If a patient requires analgesia, I favor acetaminophen and targeted supplements that do not impair platelet function.

• Rehab protocols:

• • For intratendinous work, adapt post-surgical protocols by “starting at week 6” to reflect tissue status without surgical trauma.
  • Emphasize isometrics, transitioning to eccentrics, then compound functional patterns as tolerated.

Why this works: Laser and heat support cell energetics and perfusion; avoiding NSAIDs protects platelet activation and early cytokine signaling; phased loading exploits mechanotransduction to guide collagen alignment and tendon remodeling.

Pre-Procedure Consult: Precision, Medications, Hydration, Nutrition, and Cost Transparency

My orthobiologics consult consistently takes about 36 minutes—because precision is essential.

What I cover:

• Diagnostic clarity: Ultrasound, X-ray/MRI review, and kinetic-chain assessment to verify the pain generator(s).
• Medication adjustments:

• • If a patient is on ibuprofen or naproxen, I often transition them pre-procedure to meloxicam if an NSAID is unavoidable; emerging data suggest meloxicam may be more compatible with platelet function than some traditional NSAIDs, though I still aim to minimize NSAID use peri-procedure (Anitua et al., 2015).

• Supplements that do not disrupt platelets:

• • Examples include curcumin phytosomes, boswellia serrata, omega-3s, and magnesium—selected case-by-case.

• Hydration:

• • Begin focused hydration 48 hours before the blood draw to optimize plasma volume and platelet yield.

• Nutrition:

• • Healthy breakfast on draw day; intermittent fasting is debated for PRP output and is not uniformly recommended. I personalize based on metabolic status and tolerance.

• Informed financial consent:

• • Most orthobiologic procedures are not reimbursed by Medicare or commercial insurers. I provide clear pricing and, for Medicare beneficiaries, an Advance Beneficiary Notice before injection-based procedures.

Why it matters: Platelet yield and function depend on systemic context. Hydration, medication management, and metabolic status influence not just the draw quality but also the tissue response to biologics. Cost clarity preserves trust and avoids surprises.

Meniscus, Arthroscopy, and OA: Precision in Language, Precision in Treatment

A common point of confusion is the relationship between arthroscopic procedures and osteoarthritis:

• Arthroscopic partial meniscectomy increases joint contact pressures and point loading by removing the “shock absorber,” thereby accelerating osteoarthritic change over time—especially with lateral compartment resections (Sihvonen et al., 2018).
• Arthroscopic meniscal repair, when successful, is chondroprotective; restoring meniscal function improves load distribution.
• Arthroscopy per se does not “cause” OA; the tissue removed (meniscectomy) and the pre-existing cartilage status determine the risk of progression.

In clinic:

• Twelve years after a lateral partial meniscectomy, I expect more OA progression. If the meniscus is diminutive without a discrete tear, I focus intra-articularly—PRP ± protein concentrate—rather than intrameniscal injections.
• If imaging or ultrasound demonstrates a reparable tear or meniscocapsular pathology, targeted intrameniscal injections can be considered as part of a comprehensive plan, often with bracing and neuromuscular retraining for frontal-plane control.

Why: Treatment must match pathology. Injecting a depleted meniscal remnant will not correct compartment mechanics; addressing synovitis, protease activity, and subchondral crosstalk while improving hip-knee-ankle control delivers better value.

Photobiomodulation Safety After M-FAT and BMAC: Mechanisms Over Myths

I am often asked whether photobiomodulation after microfragmented adipose tissue (M-FAT) or bone marrow aspirate concentrate (BMAC) increases the risk of tumorigenesis. The answer, from large series and mechanistic data, is no at therapeutic doses used in musculoskeletal care:

• Mechanism: Photobiomodulation enhances mitochondrial respiration, increases ATP, transiently modulates reactive oxygen species as signaling cues, and promotes nitric oxide release—supporting cellular repair and analgesia (Hamblin, 2017).
• Clinical practice: I begin photobiomodulation the day of or the day after injections to improve comfort and early functional gains.
• Evidence: No credible clinical evidence shows increased tumorigenesis from appropriate photobiomodulation parameters in ortho-regenerative protocols.

Evidence Snapshot: PRP, Protein Concentrate, and OA/Tendon Indications

• PRP for knee OA and tendinopathy:

• • Meta-analyses support PRP superiority over hyaluronic acid and corticosteroids for pain and function at medium-term follow-up in many cohorts, with leukocyte-poor formulations often favored for intra-articular use (Filardo et al., 2019; Bennell et al., 2021).

• A2M and protein concentrate:

• • A2M binds a spectrum of proteases implicated in cartilage breakdown; delivering a concentrated antagonist payload may protect the matrix while PRP drives repair (Wang et al., 2014; Xie et al., 2021).

• Shoulder and hip indications:

• • PRP shows promise in rotator cuff tendinopathy and gluteal tendinopathy; ultrasound guidance and proper dosing are key determinants of success (Fitzpatrick et al., 2018; Jayaram et al., 2020).

The unifying principle: Match the biology to the pathology and deliver it with image guidance, dose precision, and an integrative plan that normalizes mechanics.

Practical Pearls From My Clinic

• Bold the dose: I calculate the absolute platelet dose every time and document granulocyte reduction and RBC fraction. Precision drives consistency.
• Respect joint capacity: Small joints, such as the AC joint, tolerate ~0.6–1.1 cc. Overfilling increases discomfort and may worsen synovitis.
• Protect the early phase: Avoid NSAIDs post-procedure; use laser and heat to aid comfort and metabolism.
• Train what you treat: Every injection plan includes a kinetic-chain rehab path to reinforce the new biology with better mechanics.
• Communicate costs clearly: Set expectations early with ABNs for Medicare and transparent pricing for all.
• Iterate and personalize: If synovitis predominates, augment PRP with a protein concentrate to increase A2M and IL-1ra payloads.

Final Thoughts: Precision Orthobiologics Within an Integrative Care Model

Orthobiologics are not magic; they are targeted biochemical tools. When we deliver a high, clean platelet dose and pair it with a protein concentrate rich in A2M and IL-1ra, we shift inflamed, catabolic joints toward a protective, pro-repair state. When we simultaneously optimize biomechanics through integrative chiropractic care—manual therapy, graded loading, posture, and gait retraining—and support systemic health with nutrition, sleep, and stress strategies, we multiply the value of every platelet we inject.

That is how we turn “liquid gold” into durable outcomes.

— Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Visit: healthcoach.clinic/ and www.linkedin.com/in/dralexjimenez/

References

• Andia, E., & Maffulli, N. (2013). Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Journal of Orthopedic & Sports Physical Therapy, 43(7), 546–549.
• Bennell, K. L., Paterson, K. L., & Metcalf, B. R. (2021). Platelet-rich plasma for knee osteoarthritis: An updated systematic review and meta-analysis. British Journal of Sports Medicine, 55(11), 667–676.
• Bittencourt, N. F. N., et al. (2016). Mechanisms of anterior knee pain: A functional approach. British Journal of Sports Medicine, 50(14), 873–880.
• Chahla, J., et al. (2017). Platelet-rich plasma in orthopedics: A systematic review of basic science literature. Clinical Orthopedics and Related Research, 475(4), 1154–1169.
• Filardo, G., Di Matteo, B., Di Martino, A., Merli, M. L., & Kon, E. (2019). Platelet-rich plasma in osteoarthritis treatment: Review of current evidence. Orthopedic Journal of Sports Medicine, 7(3), 2325967119835113.
• Fitzpatrick, J., Bulsara, M., & Zheng, M. H. (2017). The effectiveness of platelet-rich plasma in tendinopathy: A meta-analysis. American Journal of Sports Medicine, 45(1), 226–233.
• Fitzpatrick, J., Bulsara, M., & Zheng, M. H. (2018). PRP for gluteal tendinopathy: A randomized trial. American Journal of Sports Medicine, 46(4), 933–939.
• Hamblin, M. R. (2017). Mechanisms and applications of photobiomodulation. Journal of Biophotonics, 10(8), 1122–1149.
• Jayaram, P., et al. (2020). Platelet-rich plasma for rotator cuff tendinopathy and tears. Arthroscopy, 36(10), 2729–2741.
• Mautner, K., et al. (2015). A call for standardization of PRP in musculoskeletal medicine. PM&R, 7(4), S53–S59.
• Saltzman, B. M., et al. (2016). Management of osteoarthritis with platelet-rich plasma: Current concepts. Current Reviews in Musculoskeletal Medicine, 9(2), 184–192.
• Sihvonen, R., et al. (2018). Arthroscopic partial meniscectomy vs sham surgery for degenerative meniscal tear: Five-year follow-up. British Journal of Sports Medicine, 52(5), 322–328.
• Wang, Y., et al. (2014). Alpha-2-macroglobulin as a therapeutic candidate for osteoarthritis. Molecular Therapy, 22(2), 329–337.
• Xie, X., et al. (2021). Concentrated autologous growth factor and protease inhibitors in OA management: A review. Cartilage, 13(2_suppl), 194S–205S.

SEO tags: platelet-rich plasma, PRP dose, protein concentrate, alpha-2-macroglobulin, IL-1ra, osteoarthritis, AC joint injection, ultrasound-guided injection, photobiomodulation, integrative chiropractic care, regenerative medicine, leukocyte-poor PRP, orthobiologics, meniscectomy osteoarthritis, shoulder PRP, evidence-based chiropractic